A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

摘要: The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NSCLC) launched the era personalized medicine advanced NSCLC, leading to a dramatic shift therapeutic landscape this disease. After ten years from individuation activating tyrosine kinase domain EGFR NSCLC patients responding inhibitor (TKI) Gefitinib, several progresses have been done and first line treatment with TKIs is firmly established option EGFR-mutated patients. During last decade, different developed three inhibitors approved so far these selected However, despite great breakthroughs made, molecularly poses novel challenges, such as emerging acquired resistance, brain metastases development or need translate treatments earlier clinical settings, adjuvant therapy. aim paper provide comprehensive review major reported inhibition molecularly-selected subgroup patients, early successes generation TKIs, Erlotinib irreversible mutant-selective ultimately challenges that we, next future, are called deal with.